These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 11536225)

  • 41. Phylogeny and resistance profiles of HIV-1 POL sequences from rectal biopsies and blood.
    Katzenstein TL; Petersen AB; Storgaard M; Obel N; Jensen-Fangel S; Nielsen C; Jørgensen LB
    J Med Virol; 2010 Jul; 82(7):1103-9. PubMed ID: 20513071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART.
    Lafeuillade A; Khiri H; Chadapaud S; Hittinger G; Halfon P
    AIDS; 2001 Oct; 15(15):1965-9. PubMed ID: 11600824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
    Rousseau MN; Vergne L; Montes B; Peeters M; Reynes J; Delaporte E; Segondy M
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):36-43. PubMed ID: 11176267
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.
    Richard N; Juntilla M; Abraha A; Demers K; Paxinos E; Galovich J; Petropoulos C; Whalen CC; Kyeyune F; Atwine D; Kityo C; Mugyenyi P; Arts EJ
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):355-64. PubMed ID: 15157354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
    Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
    Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
    Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
    Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female.
    Tirado G; Jove G; Kumar R; Noel RJ; Reyes E; Sepulveda G; Yamamura Y; Kumar A
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):684-6. PubMed ID: 15242547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
    Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
    AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
    Cabana M; Clotet B; Martínez MA
    J Med Virol; 1999 Dec; 59(4):480-90. PubMed ID: 10534730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.
    Günthard HF; Wong JK; Ignacio CC; Guatelli JC; Riggs NL; Havlir DV; Richman DD
    J Virol; 1998 Mar; 72(3):2422-8. PubMed ID: 9499103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency of protease and reverse transcriptase drug resistance mutations in naïve HIV-infected patients.
    Valle-Bahena OM; Ramos-Jiménez J; Ortiz-López R; Revol A; Lugo-Trampe A; Barrera-Saldaña HA; Rojas-Martínez A
    Arch Med Res; 2006 Nov; 37(8):1022-7. PubMed ID: 17045121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
    Wilson JW; Bean P; Robins T; Graziano F; Persing DH
    J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV-1C proviral DNA for detection of drug resistance mutations.
    Huruy K; Mulu A; Liebert UG; Maier M
    PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.